Literature DB >> 19482250

Hepatic complications of breast cancer.

Jennifer R Diamond1, Christina A Finlayson, Virginia F Borges.   

Abstract

Hepatic disease associated with breast cancer is common and can result from metastatic spread of the tumour to the liver, or can be caused by systemic treatment with chemotherapeutic or antiendocrine agents. Metastatic disease to the liver can present clinically and pathologically in various ways. Little is known as to why breast cancer can sometimes present as liver dominant disease or with liver involvement as a late event in the disease course. However, there are many postulations involving metastasis organotropism, which might offer future insight. The mainstay of treatment for hepatic metastases continues to be systemic therapy, but several locoregional adjunct therapies exist. Despite these therapies, liver metastasis from breast cancer is associated with a poor prognosis. Ongoing research of the mechanisms and tropism of liver metastasis from breast cancer will hopefully result in improved targeted therapies to reduce their incidence and improve outcomes when they arise.

Entities:  

Mesh:

Year:  2009        PMID: 19482250     DOI: 10.1016/S1470-2045(09)70029-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  22 in total

Review 1.  [Multimodality treatment concepts for metastatic breast cancer].

Authors:  V Heinemann; S Kahlert; H-J Stemmler
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

2.  Metastatic breast cancer presenting as acute liver failure.

Authors:  Hector E Nazario; Rita Lepe; James F Trotter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

Review 3.  The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

Review 4.  Breast cancer liver metastasis: current and future treatment approaches.

Authors:  Narmeen S Rashid; Jacqueline M Grible; Charles V Clevenger; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2021-03-06       Impact factor: 5.150

5.  Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance.

Authors:  Yvonne Chao; Qian Wu; Christopher Shepard; Alan Wells
Journal:  Clin Exp Metastasis       Date:  2011-10-02       Impact factor: 5.150

6.  Survivin is a novel target of CD44-promoted breast tumor invasion.

Authors:  Mohamed E Abdraboh; Rajiv L Gaur; Andrew D Hollenbach; Dane Sandquist; Madhwa H G Raj; Allal Ouhtit
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

7.  Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin.

Authors:  Mariela N Macias; Daniel Sanghoon Shin; Blanca Ledezma; Saeed Sadeghi
Journal:  BMJ Case Rep       Date:  2014-06-04

8.  Radiographically occult intrasinusoidal liver metastases leading to hepatic failure in a case of breast cancer.

Authors:  Seema Gulia; Sachin Khurana; Tanuja Shet; Sudeep Gupta
Journal:  BMJ Case Rep       Date:  2016-02-15

9.  Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies.

Authors:  Mitsuhiro Furuta; Junichiro Watanabe; Takeshi Aramaki; Akifumi Notsu; Hirofumi Yasui
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

10.  Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.

Authors:  Guido Giordano; Antonio Febbraro; Erica Quaquarini; Anna Turletti; Rebecca Pedersini; Mimma Raffaele; Federica Villa; Rosalba Rossello
Journal:  Oncology       Date:  2018-07-24       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.